Elderly AML & Burkitt Lymphoma Updates
from OncoPharm Hosted by John Bossaer
Aggressive hematologic malignancy publications can be challenging to interpret and translate to clinical practice. We look at two recent studies to illustrate this point. Elderly AML: 10-day decitabine vs. 7 + 3 (https://doi.org/10.1016/S2352-3026(23)00273-9) Burkitt Lymphoma: R-CODXO-M/R-IVAC vs. DA-R-EPOCH (https://doi.org/10.1016/S2352-3026(23)00279-X)
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of OncoPharm?
This episode is 24 minutes long.
When was this OncoPharm episode published?
This episode was published on November 9, 2023.
Can I download this OncoPharm episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.